S100B and Parkinson disease: PTM administration has also been shown to ameliorate clinical and/or neuropathologic/biomolecular parameters in other disorders involving the nervous system, such as AD, PD, sepsis-associated encephalopathy, and bowel inflammation, where its action has been reasonably attributed to the block of S100B activity [49,50,51].